TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 409-418

  Kvistborg, Pia ^a   Shu, Chengyi Jenny ^a   Heemskerk, Bianca ^a   Fankhauser, Manuel ^a   Thrue, Charlotte Albæk ^b   Toebes, Mireille ^a   Van Rooij, Nienke ^a   Linnemann, Carsten ^a   Van Buuren, Marit M ^a   Urbanus, Jos H M ^a   Beltman, Joost B ^c   Straten, Perthor ^b   Li, Yong F ^d   Robbins, Paul F ^d   Besser, Michal J ^e,f   Schachter, Jacob ^e   Kenter, Gemma G ^a   Dudley, Mark E ^d   Rosenberg, Steven A ^d   Haanen, John B A G ^a   Hadrup, Sine Reker ^b   Schumacher, Ton N M ^a   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UTRECHT UNIVERSITY   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SHEBA MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

High throughput screening; PMHC multiplexing; T cell reactivity; TIL therapy; Tumor immunology

Indexed keywords

CYCLIN DEPENDENT KINASE 4; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; MELOE 1 ANTIGEN; NY ESO 1 ANTIGEN; SURVIVIN; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE PROFILING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; LYMPHOCYTE SUBPOPULATION; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR INFILTRATING T LYMPHOCYTE THERAPY;

EID: 84886944933     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.18851     Document Type: Article

References (26)

1. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229:67-87; PMID:19426215; http://dx.doi.org/10.1111/j.1600-065X.2009.00763.x
2. Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CG, McDermott DF, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. ASCO Annual Meeting Proceedings 2010; 28:2506.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. + T cells: Correlation with clinical outcomes. ASCO Annual Meeting Proceedings 2010; 28:2555.
5. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccinationcombined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267-76; PMID:19789309; http://dx.doi.org/10.1158/1078-0432.CCR-09-1254
6. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensivemyeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
7. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
8. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16:6122-31; PMID:20668005; http://dx.doi.org/10.1158/1078-0432.CCR-10-1297
9. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51; PMID:16462803; http://dx.doi.org/10.1038/nm1360
10. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520-6; PMID:19543285; http://dx.doi.org/10.1038/nmeth.1345
11. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31:742-51; PMID:18779745; http://dx.doi.org/10.1097/CJI.0b013e31818403d5
12. Johnson LA, Heemskerk B, Powell DJ, Jr., Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumorreactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006; 177:6548-59; PMID:17056587
13. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68:889-92; PMID:18245491; http://dx.doi.org/10.1158/0008-5472.CAN-07-3095
14. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208; PMID: 16551247; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090733
15. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006; 92:187-224; PMID:17145305; http://dx.doi.org/10.1016/S0065-2776(06)92005-7
16. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24; PMID: 21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537
17. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9:998-1008; PMID:12631598
18. Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71:1253-62; PMID: 21216894; http://dx.doi.org/10.1158/0008-5472.CAN-10-2693
19. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-86; PMID:16061727; http://dx.doi.org/10.1084/jem.20040613
20. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirusspecific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51:591-9; PMID:21133926; http://dx.doi.org/10.1111/j.1537-2995.2010.02940.x
21. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31:199-206; PMID:18481389; http://dx.doi.org/10.1097/CJI.0b013e31815ef862
22. Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, et al. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cellsto increase biosafety. J Immunother 2007; 30:817-24; PMID:18049333; http://dx.doi.org/10.1097/CJI.0b013e318155a11c
23. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genomewide somatic mutation studies of cancer. Genomics 2009; 93:17-21; PMID:18692126; http://dx.doi.org/10.1016/j.ygeno.2008.07.005
24. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al & NISC Comparative Sequencing Program. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43:442-6; PMID:21499247; http://dx.doi.org/10.1038/ng.810
25. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al & BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
26. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with singleantigenic peptides. Proc Natl Acad Sci U S A 1992; 89:3429-33; PMID:1565634; http://dx.doi.org/10.1073/pnas.89.8.3429